Multiple studies have reported the development and characterization of neutralizing monoclonal antibodies, the majority of which target the RBD of the SARS‐CoV‐2 spike (S) glycoprotein and inhibit ACE2 binding.[44] Our results highlight the potential for the selective activation of T‐cell immunity as a method for developing monoclonal antibody‐based therapies with increased potency and improved therapeutic efficacy against COVID‐19, especially in the aged population. Here, ACE2 is linked to COVID-19.